Schering Noxafil Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering-Plough's triazole antifungal Noxafil (posaconazole oral suspension) shows significantly better results than standard antifungals in a study presented Dec. 8 at the American Society of Hematology meeting. Overall success rate was 42% in patients receiving Noxafil 800 mg/day for up to one year, vs. 26% for standard therapy (p=0.006). Noxafil is one of three launches Schering is anticipating by 2007; the firm also expects to introduce the oncologic Sarasar (lonafarnib) and a fixed combination of Zetia and Zocor, which is pending at FDA with a July user fee goal...